MX2021009885A - Composicion farmaceutica oral con un alcaloide vegetal para el tratamiento de dependencias. - Google Patents

Composicion farmaceutica oral con un alcaloide vegetal para el tratamiento de dependencias.

Info

Publication number
MX2021009885A
MX2021009885A MX2021009885A MX2021009885A MX2021009885A MX 2021009885 A MX2021009885 A MX 2021009885A MX 2021009885 A MX2021009885 A MX 2021009885A MX 2021009885 A MX2021009885 A MX 2021009885A MX 2021009885 A MX2021009885 A MX 2021009885A
Authority
MX
Mexico
Prior art keywords
composition
alkaloid
pharmaceutical composition
oral
treatment
Prior art date
Application number
MX2021009885A
Other languages
English (en)
Inventor
Angel Aleksiev Aleksiev
Veselin Evgeniev Daskalov
Original Assignee
Sopharma Ad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sopharma Ad filed Critical Sopharma Ad
Publication of MX2021009885A publication Critical patent/MX2021009885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral que contiene un agente colinérgico, un alcaloide vegetal natural en particular, seleccionado del grupo de la lobelina, la anabasina, la citisina, la galantamina o sus sales farmacéuticamente aceptables, en forma de comprimidos y cápsulas. Los excipientes de la composición oral obtenida incluyen polvo de celulosa, sulfato de calcio, sílice coloidal y estearato de magnesio, en donde el contenido total del polvo de celulosa y de sulfato de calcio dihidratado es de 64.5 a 97.5 % de la masa de la forma farmacéutica, y en donde al menos el 90% de las partículas de alcaloide es = 100 µm. La composición oral contiene asimismo al menos un aminoácido biológicamente activo seleccionado de: L-carnitina, triptófano o una combinación de ambos. La composición oral de conformidad con la presente invención permite una distribución uniforme del principio activo en la composición, así como la estabilidad de la composición debido a los excipientes incluidos seleccionados, de forma que reaccionen al mínimo con el alcaloide para formar las sustancias correspondientes de forma cualitativa y cuantitativamente apropiada para la composición farmacéutica. La composición de conformidad con la presente invención se puede aplicar para el tratamiento de la dependencia y la adicción a la nicotina, a los productos del tabaco y al alcohol.
MX2021009885A 2019-04-12 2019-11-28 Composicion farmaceutica oral con un alcaloide vegetal para el tratamiento de dependencias. MX2021009885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG112910A BG67408B1 (bg) 2019-04-12 2019-04-12 Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
PCT/BG2019/000027 WO2020206511A1 (en) 2019-04-12 2019-11-28 Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies

Publications (1)

Publication Number Publication Date
MX2021009885A true MX2021009885A (es) 2021-09-14

Family

ID=69137657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009885A MX2021009885A (es) 2019-04-12 2019-11-28 Composicion farmaceutica oral con un alcaloide vegetal para el tratamiento de dependencias.

Country Status (13)

Country Link
US (1) US20210275460A1 (es)
EP (1) EP3952845A1 (es)
JP (1) JP2022528299A (es)
KR (1) KR20210153044A (es)
CN (1) CN113194930A (es)
AU (1) AU2019440193A1 (es)
BG (1) BG67408B1 (es)
BR (1) BR112021011125A2 (es)
CA (1) CA3126725C (es)
EA (1) EA202191589A1 (es)
MX (1) MX2021009885A (es)
WO (1) WO2020206511A1 (es)
ZA (1) ZA202105144B (es)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5414005A (en) * 1993-10-28 1995-05-09 Dynagen, Inc. Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
DE4301782C1 (de) 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
RU2134585C1 (ru) 1997-08-28 1999-08-20 Закрытое акционерное общество "Эвалар" Биологически активная добавка к пище "коррида" для отвыкания от курения
RU2125883C1 (ru) 1997-09-18 1999-02-10 Медведев Виктор Михайлович Сбор "колдунок" лекарственных растений, обладающий успокаивающим и антиникотиновым действием
CA2358062C (en) 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
RU2157704C2 (ru) 1998-12-28 2000-10-20 Алферов Виктор Петрович Антиникотиновое антиалкогольное изделие
US6534527B2 (en) * 2000-06-02 2003-03-18 Phytos, Inc. Edible herbal compositions for relieving nicotine craving
JP3730522B2 (ja) 2000-07-21 2006-01-05 太陽化学株式会社 喫煙欲求抑制組成物
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US20050123502A1 (en) * 2003-10-07 2005-06-09 Chan Shing Y. Nicotine containing oral compositions
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
US20080103111A1 (en) 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
CN101342173A (zh) * 2007-07-13 2009-01-14 和泓生物技术（上海）有限公司 洛贝林在制备治疗神经元凋亡疾病的药物中的应用
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2738125T3 (es) 2008-12-23 2020-01-20 Wing Win Consulting Ltd Sistema de comunicación móvil que comprende una celda en un modo de acceso híbrido
CA2781826A1 (en) * 2009-11-26 2011-06-03 Usv Limited Controlled release pharmaceutical compositions of galantamine
CA2861995C (en) * 2012-01-20 2021-10-26 Altria Client Services Inc. Oral product comprising a mouth-stable polymer matrix and fibers
PL220354B1 (pl) * 2012-11-19 2015-10-30 Aflofarm Fabryka Leków Spółka Z Ograniczoną Odpowiedzialnością Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
CN103284319A (zh) 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
PL408608A1 (pl) * 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
RU2572720C1 (ru) * 2014-07-29 2016-01-20 Дмитрий Евгеньевич Денисов Комплексное антиникотиновое средство
RU2593585C1 (ru) 2015-06-26 2016-08-10 Общество с ограниченной ответственностью "Ритек-Фарма" Способ лечения табакокурения и других форм никотиновой зависимости, а также профилактики рецидивов табакокурения
CN107744508A (zh) * 2017-10-14 2018-03-02 威海贯标信息科技有限公司 一种氢溴酸加兰他敏片剂

Also Published As

Publication number Publication date
CA3126725C (en) 2023-10-17
EA202191589A1 (ru) 2021-07-26
KR20210153044A (ko) 2021-12-16
AU2019440193A1 (en) 2021-06-17
US20210275460A1 (en) 2021-09-09
ZA202105144B (en) 2022-09-28
CA3126725A1 (en) 2020-10-15
BG112910A (bg) 2020-10-30
WO2020206511A1 (en) 2020-10-15
JP2022528299A (ja) 2022-06-10
CN113194930A (zh) 2021-07-30
EP3952845A1 (en) 2022-02-16
BR112021011125A2 (pt) 2021-11-16
BG67408B1 (bg) 2022-01-17

Similar Documents

Publication Publication Date Title
US10111831B2 (en) Chewable vehicle for mouth absorption
TWI314868B (en) Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient
Takamiya et al. Effect of smoking on the survival of dental implants
JP2010518822A (ja) ビタミンおよびミネラル補助食品における改善された安定性
JP2010518822A5 (es)
Kichko et al. Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons
BR112013026236B1 (pt) Comprimido de liberação controlada de extrato de ginkgo biloba e processo para a obtenção do mesmo
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
JP2013116889A (ja) 防已含有組成物
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
Keny et al. Formulation and evaluation of rizatriptan benzoate mouth disintegrating tablets
MX2021009885A (es) Composicion farmaceutica oral con un alcaloide vegetal para el tratamiento de dependencias.
Alburyhi et al. Formulation and Evaluation of Drotaverine Orally Disintegrating Tablets
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
SG183449A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
WO2018011470A1 (en) A snuff-type composition and method and uses related thereto
Bichewar et al. Formulation and Evaluation of Chronomodulated drug delivery system of Doxofylline for treatment of Nocturnal Asthma
Borde et al. Formulation and evaluation of Paliperidone HCl mouth dissolving tablet by QbD approach
Panthi FORMULATION AND DEVELOPMENT OF AMISULPRIDE TABLETS AND IT'S COMPARATIVE EVALUATION OF PHYSICAL AND CHEMICAL PARAMETERS BETWEEN ACCELERATED AND REAL TIME STABILITY
Struk et al. Development of composition and technology of effervescent tablets with acetylsalicylic acid, paracetamol and caffeine
RU2205636C1 (ru) Средство для профилактики вредного воздействия табачного дыма и других продуктов горения
EA032932B1 (ru) Лекарственная форма, содержащая натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат, и способ ее получения
Khan et al. Formulation and evaluation of methylphenidate hydrochloride fast dissolving tablet by QbD approach
WO2017083615A1 (en) An energy cigar and method for making same
JP2017525773A (ja) 急性疼痛治療用フィルムコーティング錠剤